PTO/SB/05 (11-00) 😙 or use through 10/31/2002. OMB 0651-0032 Approved

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE L.

Please type a plus sign (+) inside this box Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION **TRANSMITTAL**

A065 US Attorney Docket No. Pepinsky First Inventor

Polymer Conjugates of Interferon Beta-1a and Use EL 475127496US Express Mail Label No.

(Only for new nonprovisional applications under 37 CFR 1.53(b)) Assistant Commissioner for Patents Box Patent Application ADDRESS TO: APPLICATION ELEMENTS Washington, DC 20231 See MPEP chapter 600 concerning utility patent application contents. CD-ROM or CD-R in duplicate, large table or Fee Transmittal Form (e.g., PTO/SB/17) Computer Program (Appendix) (Submit an original and a duplicate for fee processing) 8. Nucleotide and/or Amino Acid Sequence Submission Applicant claims small entity status. (if applicable, all necessary) See 37 CFR 1.27 Computer Readable Form (CRF) Specification [Total Pages (preferred arrangement set forth below) 3. **X** Specification Sequence Listing on: - Descriptive title of the invention i. Z CD-ROM or CD-R (2 copies); or - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D ii. 🗶 paper - Reference to sequence listing, a table, c. X Statements verifying identity of above copies or a computer program listing appendix - Background of the Invention ACCOMPANYING APPLICATION PARTS - Brief Summary of the Invention - Brief Description of the Drawings (if filed) Assignment Papers (cover sheet & document(s)) - Detailed Description Power of 37 CFR 3.73(b) Statement - Claim(s) Attorney 10. (when there is an assignee) - Abstract of the Disclosure English Translation Document (if applicable) Copies of IDS Drawing(s) (35 U.S.C. 113) [Total Sheets Information Disclosure 4. Citations Statement (IDS)/PTO-1449 [Total Pages 5. Oath or Declaration Preliminary Amendment 13. Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d)) Return Receipt Postcard (MPEP 503) 14. (Should be specifically itemized) (for continuation/divisional with Box 18 completed) Certified Copy of Priority Document(s) (if foreign priority is claimed) **DELETION OF INVENTOR(S)** 15. Request and Certification under 35 U.S.C. 122 Signed statement attached deleting inventor(s) (b)(2)(B)(i). Applicant must attach form PTO/SB/35 named in the prior application, see 37 CFR 16 1.63(d)(2) and 1.33(b). or its equivalent next Declaration/Power Application Data Sheet. See 37 CFR 1.76 17. **X** Other: 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, of prior application No.: PCT/US99/24201or in an Application Data Sheet under 37 CFR 1.76: Continuation-in-part (CIP) Divisional Continuation Group Art Unit: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS Correspondence address below (Insert Customer No. or Attach bar code label here) Customer Number or Bar Code Label Raymond G. Arner Name BIOGEN, INC. 14 Cambridge Center 02142 Zip Code Address State MA Cambridge (617) 679-2838 City Fax (617) 679-2857 Telephone US Country 32,958 Registration No. (Attorney/Agent) Name (Print/Type) Buch Date

Burden Hour Statement: This form is estimated to take 8.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents. Box Patent Application, Washington, DC 20231.

PTO/SB/17 (09-00)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE o a collection of information unless it displays a valid OMB control number

Under the Paperwork Reduction Act of 1995, no persons are required to re

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

Signature

(\$) 1,706	(\$) 1,	706
------------	---------	-----

U.S. Patent and Tra spond to a collection of infor	mation unless it displays a valid OMB control number
Co	mplete if Known
Application Number	
Filing Date	D. Sanky
First Named Inventor	Pepinsky
Examiner Name	
Group Art Unit	1005 NG
Attorney Docket No.	A065 US

TOTAL AMOUNT OF PAYMENT	(\$) 1,706	Attorney Docket No.	A003 C3	
		FEE C	ALCULATION (continued)	
METHOD OF PAYN	ENT	3. ADDITIONAL FEES		
The Commissioner is hereby auth indicated fees and credit any ove	norized to charge rpayments to:	Large Entity Small Entity Fee Fee Fee Fee Fee (\$)	Fee Description	Fee Paid
Account Number U2-2327		100 100 =	harge - late filing fee or oath harge - late provisional filing fee or	
Deposit Account Name BIOGEN, INC.		cove	r sheet -English specification	
Charge Any Additional Fee Required		155 155 117 2 520 For	filing a request for ex parte reexamination	
Applicant claims small entity status.		112 920* 112 920* Req	uesting publication of SIR prior to miner action	
See 37 CFR 1.27 2. Payment Enclosed:	Money Other	113 1,840* 113 1,840* Red Exa	questing publication of SIR after miner action	
Check Credit card	Order Other	115 110 215 55 Ext	tension for reply within first month	
FEE CALCULAT	ION	140 200 216 195 Ext	ension for reply within second month	
1. BASIC FILING FEE		447 000 017 445 Ext	ension for reply within third month	
Large Entity Small Entity		118 1,390 218 695 Ext	tension for reply within fourth month	
Fee Fee Fee Fee	Fee Paid		tension for reply within fifth month	
Code (\$) Code (\$) 101 710 201 355 Utility filing f	ee 710	119 310 219 155 No	otice of Appeal	
one see Design filing			ing a brief in support of an appeal	
245 Plant filing f		004 425 Re	equest for oral hearing	
107 100 -		128 1 510 138 1,510 Pe	etition to institute a public use proceeding	
700 7.5 Travisional		140 110 240 55 Pe	etition to revive - unavoidable	
114 150 2	510	141 1 240 241 620 Pe	etition to revive - unintentional	
SUBTOTA	(L (1) [(Ψ)	142 1,240 242 620 UI	tility issue fee (or reissue)	
2. EXTRA CLAIM FEES	Fee from	143 440 243 220 D	esign issue fee	
Extra Cla	ims below Fee Pa	144 600 344 300 P	Plant issue fee	
Total Claims $47 - 20^{**} = 27$		= 100 122 130 P	Petitions to the Commissioner	
Independent 6 - 3** = 3	x 80 = 240	= 100 50 103 50 F	Petitions related to provisional applications	
Claims Multiple Dependent	270 = 270		Submission of Information Disclosure Stmt	
Total Control Entity		120 240	Recording each patent assignment per property (times number of properties)	
Fee Fee Fee Fee Fee Code (\$)	escription excess of 20	146 710 246 355	Filing a submission after final rejection (37 CFR § 1.129(a))	
103 10 202 40 Independ	dent claims in excess of 3	149 110 -11	For each additional invention to be examined (37 CFR § 1.129(b))	
104 270 204 135 Multiple	dependent claim, if not pai	179 710 279 355	Request for Continued Examination (RCE	Ē)
109 80 209 40 ** Reiss over 0	ue independent claims riginal patent		Request for expedited examination of a design application	
110 18 210 9 ** Reiss and o	ver original patent	Other fee (specify)		
SUBTOTA	L (2) (\$) 996	Reduced by Basic Filing		
**or number previously paid, if grea	iter; For Reissues, see abo		Complete (if applicable)	
SUBMITTED BY		Registration No.	32.958 Telephone (6)	(7) 679-2857
Name (Print(Type)	Raymond/G. Apper	(Attorney/Agent)		11/201
1.0110 (1.1111)	11/1/1/1/1		Date 77 7 D	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

ERTIFICATE OF Molicant(s): Pepinsky, e		MAIL" (37 CFR 1.1	Docket No. A065 US
Serial No.	Filing Date herewith	Examiner	Group Art Unit
ention: Polymer Con	jugates of Interferon Beta-1a an	d Uses	09/8375
			•
Declaration/Po	ower of Attorney	, sequence (disk, copy and statement) (Identify type of correspondence)	
Declaration/Po Application as is being deposited wi	ower of Attorney and Drawings the United States Postal Selevelope addressed to: The Assistant 2001	, sequence (disk, copy and statement) (Identify type of correspondence) rvice "Express Mail Post Office to A stant Commissioner for Patents, Wa	Addressee" service unde
Application as is being deposited wi	ower of Attorney and Drawings the United States Postal Selevelope addressed to: The Assistant 2001	rvice "Express Mail Post Office to A stant Commissioner for Patents, Wa	addressee" service unde ashington, D.C. 20231 o
Declaration/Po Application as is being deposited with 37 CFR 1.10 in an en	ower of Attorney and Drawings the United States Postal Selevelope addressed to: The Assistant 2001	rvice "Express Mail Post Office to A stant Commissioner for Patents, Wastant Commissioner for Patents fo	addressee" service undershington, D.C. 20231 o
Declaration/Po Application as is being deposited wi	ower of Attorney and Drawings the United States Postal Selevelope addressed to: The Assistant 2001	rvice "Express Mail Post Office to A stant Commissioner for Patents, Wa	addressee" service undershington, D.C. 20231 of tter titer white the correspondence of

Note: Each paper must have its own certificate of mailing.